ABSTRACT OBJECTIVE: Primary pigmented nodular adrenocortical disease (PPNAD), an uncommon cause of Cushing's syndrome, is frequently associated with a wider clinical spectrum, the Carney complex (CC), a multiple endocrine neoplasia syndrome. DESIGN: We evaluated a low-dose mitotane regimen for treating severe hypercortisolism in a 27-year-old woman with CC. She presented with severe hypercortisolism and a history of surgeries for breast ductal adenoma, atrial cardiac myxomas with cerebral and peripheral arterial embolism, and neartotal thyroidectomy because of an oxyphilic adenoma. The patient refused further surgery for adrenalectomy. RESULTS: During the first 7 months of mitotane (Lysodren, HRA Pharma, Paris, France), the daily oral dose was progressively increased from 0.5 to 4 g/day and then stopped because of the appearance of sustained signs of hypoadrenalism, that required a replacement therapy with 5 mg of prednisone o.d. A 10-month mitotane off-therapy follow-up was performed and when an increase in urine free cortisol (UFC) was noted, the mitotane regimen was restarted at lower doses (0.750-1 g/day). Serum morning cortisol levels and UFC were then maintained within the normal range, with plasma mitotane ranging between 2 and 4 mg/L. A sustained regression of Cushing's features without inducing hypoadrenalism was achieved, which still persists after 122 months of follow-up. Minimal initial gastric discomfort was the only side effect of which the patient complained and only during the first higher dose mitotane course. CONCLUSIONS: Long-term administration of a low maintenance dose of mitotane may be suggested as treatment for hypercortisolism in CC patients who refuse or are at high risk for surgical adrenalectomy.
INTRODUCTION
Primary pigmented nodular adrenal dysplasia (PP-NAD) is an uncommon cause of Adrenal Cushing's Syndrome (ACS).
1 PPNAD is frequently associated with a wider clinical spectrum, the Carney complex (CC), which may also include spotty skin pigmentation, heart and skin myxoma and LCCSCT (large-cell calcifying Sertoli cell tumor). CC may also be associated, although uncommonly, with acromegaly, PMS (psammomatous melanotic schwannoma), thyroid nodules or cancer, and breast ductal adenoma. 2 Carney complex is an autosomal dominant multiple endocrine neoplasia syndrome due to a mutation at the 17q22-24 locus involving the tumor suppressor gene cAMP-dependent protein kinase type I-alpha regulatory subunit (PRKAR1A), coding for the type 1 regulatory subunit of PKA. [3] [4] [5] PPNAD is associated with features of Cushing's syndrome, virilization and hypertension with a lack of cortisol suppression on high dose dexamethasone (DXT) test, and paradoxical cortisol increase after 1 mg midnight DXT test in some patients, 6 low plasma adrenocorticotropin hormone (ACTH) and absent cortisol and ACTH responses to corticotropin releasing hormone (CRH). As medical therapy of hypercortisolism is still far from providing effective and well-tolerated drugs, adrenal surgery remains the definitive solution to the syndrome.
is widely used in the treatment of adrenocortical carcinoma and Cushing's syndrome by virtue of its tissue-selective toxicity. [8] [9] [10] [11] Furthermore, mitotane may be a suitable therapeutic option for CC subjects at increased surgical risk or refusing further surgical procedures. Here we report the long-term follow up, the time-course of mitotane and the steroid serum profile of a tenyear low-dose mitotane regimen inducing correction of severe hypercortisolism in a young woman with PPNAD and CC.
PATIENT'S DESCRIPTION
A 27-year-old female CC patient had a history of surgical procedures for breast ductal adenoma, atrial cardiac myxomas with cerebral embolism and neartotal thyroidectomy because of an oxyphilic adenoma. On physical examination, the patient presented with a rounded face and virilization signs and marked atrophy of the proximal muscles. No mucocutaneous manifestations of CC were observed. Laboratory findings are reported in Table 1 . Molecular genetic analyses of the PRKAR1A gene revealed a common mutation: a 2-bp deletion of nucleotides T and G at positions 578 and 579. No mutations were revealed in the parents and in her sister. Nodular appearance of the left adrenal gland with typical "bead-on-astring" PPNAD feature of the right gland was seen on computed tomography (CT) ( Figure 1A) . We decided to start a mitotane course before a further surgical procedure, which at the time the patient refused. During the first 7 months of the course of treatment, mitotane (Lysodren, HRA Pharma, Paris, France) was increased weekly by 0.5 g up to 4 g/day and then stopped (the cumulative dose was 602 g) because of sustained signs of hypoadrenalism ( Figure  2 ). The mitotane regimen was restarted at lower doses (0.750-1 g/day) after a 10-month mitotane off-therapy since a gradual increase in UFC was noted. Serum cortisol levels and UFC were then maintained within the normal range, with plasma mitotane levels ranging between 2 and 4 mg/L (Figure 2 ). Two months from the beginning of the treatment (plasma mitotane level: 8 mg/L), a progressive regression of the typical signs of Cushing's syndrome and hyperandrogenism with restoration of regular menses was achieved. At the end of the first mitotane treatment, the size of the adrenal glands appeared to have been reduced by the adrenolytic treatment with regression of the typical CT "bead-on-a-string" PPNAD feature of the right gland ( Figure 1B) , which still persists at the 122 nd month ( Figure 1C ). Hormonal variables were measured using commercially available kits. All hormone assays were performed in the same laboratory. Plasma mitotane was determined by the HPLC method.
12 Intra-and interassay coefficients of variation for all the above mentioned variables were less than 5% and 8%, respectively.
DISCUSSION
Due to the number of neoplastic manifestations, patients with PPNAD and CC commonly undergo several surgical procedures whose risks are aggravated by the presence of hypercortisolism or sequelae from heart myxomas and related cardiac operations. Therefore, medical therapy with mitotane may be a suitable therapeutic option for such subjects. Adrenal tissue-selective mitotane toxicity is mainly due to its local metabolic transformation of mitotane into its methylsulfonyl metabolite, MeSO2-DDE [2,2-(2-chlorophenyl,4'-chlorophenyl)1,1-dichloroethane], the human adrenal cortex also being capable of forming irreversibly bound MeSO2-[
14 C]DDE-protein adducts. 8 Indeed, in our patient, by contrast to a pronounced reduction of plasma dehydroepiandrosterone sulfate (DEAS) and cortisol concentration, aldosterone levels were not affected by mitotane treatment. Donadille et al 13 described a successful treatment of hypercortisolism in 23 ectopic ACTH secretion syndrome patients with occult and/or inoperable and/or metastatic tumors or severe hypercortisolism using long-term mitotane courses with a mean therapy duration of 1.8 ± 2.1 yr (range 0.06-9.7 y) and a mean daily dose of 3.3 ± 1.2 g. In our adult PPNAD patient, we used a welltolerated low-dose mitotane regimen (0.750-1 g/day after initial dose of 4 g/day) and we obtained a longterm (10 years) complete and sustained regression of Cushing's features with a significant amelioration of quality of life. Morning serum cortisol and UFC levels were maintained within the normal range with plasma mitotane ranging between 2 and 4 mg/L, a concentration much lower than that reported for adrenal carcinoma or ectopic Cushing's syndrome patients. 14 Moreover, we observed a marked reduction in DHEAS and androstenedione serum values with restoration of ovary steroids. Furthermore, during the second low-dose mitotane regimen, menses and ovary steroid plasma levels were still maintained. Surprisingly, both the circadian rhythm of serum cortisol levels and its response to 1 mg overnight DXT suppression test, which previously demonstrated a typical paradoxical increase, returned to normal levels (Table  1) . These hormonal findings were associated with a considerable reduction in adrenal size ( Figure 1C ). Interestingly in our patient, the long-term course with low-dose mitotane did not induce hypoadrenalism. A subsequent surgical procedure for recurrence of atrial myxoma that the patient underwent was indeed well tolerated without any complications. A partial correction of bone density was also achieved. Taking into account the many surgical procedures which CC patients usually undergo, our report encourages considering low-dose mitotane treatment as a safe and effective way of achieving sustained correction of hypercortisolism by PPNAD in subjects with CC and above all for subjects at increased surgical risk or refusing further surgical procedures.
